It all comes back to their failure in the original study to show...

First 22 Last

Share
Profile

Follow
beaches811

1,531 Posts.

299

31/01/22

21:58

Post #: 59258114
Share

Originally posted by Gongboy: ↑

I think Mike's view was that you had to spend money to make money, and that is fine if you are growing revenue quickly. I did once look at how much each sales person sold against their salary (cant recall the figure) but it was quite astounding how little they each sold. Their business model relied of rapid uptake in the US (this is already the most expensive medicine in the world, so you would think that another $350 for DyeVert would have been easy). But it wasn't - and still isn't. You would think insurers would be pushing it if it reduced hospital costs - but they don't seem to be, and you would think hospitals and doctors would be sued for not using the latest available tech to reduce complications.

When (if) they get it on the UK NHS you will know that it is truly cost effective in practice.

If you look at the current MC (about $12 million), and strip out the cash though, it is quite a cheap company now and the tech should have value to someone.

Expand

It all comes back to their failure in the original study to show that it affected mortality rates. That is what really killed it, after that they were flogging a dead horse. I had invested previously until I worked out what was really going on.

OSP Price at posting: 48.0¢ Sentiment: Sell Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights: RIP to Botanix (for now); Droneshield new ATH; Trigg mystery halt

LIS

'Opens doors': Li-S Energy the first Oz company to produce lithium metal foils

AAU

Antilles brings Chinese ally on board to keep Neuva Sabana work chugging on

AII

Inside the depths of Panasqueira: A legacy carved in rock

VMM

'Big tick': Viridis positions for global leadership with Colossus pre-feasibility study

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Trump just dropped a 200% tariff bomb. Here's how to cash in

CWX

Carawine faces Fraser Range JV collapse as IGO moves to scrap partnership

ILU

Rare earths stocks surge as Pentagon buys big stake in US REE miner

Week 28 Wrap: Tariff chaos back for some reason; CBA holds strong

First 22 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

It all comes back to their failure in the original study to show...

Top Stories

HotCopper Highlights: RIP to Botanix (for now); Droneshield new ATH; Trigg mystery halt

'Opens doors': Li-S Energy the first Oz company to produce lithium metal foils

Antilles brings Chinese ally on board to keep Neuva Sabana work chugging on

Inside the depths of Panasqueira: A legacy carved in rock

'Big tick': Viridis positions for global leadership with Colossus pre-feasibility study

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Trump just dropped a 200% tariff bomb. Here's how to cash in

Carawine faces Fraser Range JV collapse as IGO moves to scrap partnership

Rare earths stocks surge as Pentagon buys big stake in US REE miner

Week 28 Wrap: Tariff chaos back for some reason; CBA holds strong

Featured News